Mavacamten (Camzyos®). HTA ID: 23028

Assessment Status Full HTA submission received from Applicant
HTA ID 23028
Drug Mavacamten
Brand Camzyos®
Indication Mavacamten (Camzyos®) is indicated for the treatment of symptomatic (New York Heart Association, NYHA, class II–III), obstructive hypertrophic cardiomyopathy (oHCM) in adult patients.
Assessment Process
Rapid review commissioned 19/05/2023
Rapid review completed 27/06/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of mavacamten compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 26/07/2023
Pre-submission consultation with Applicant 12/09/2023
Full submission received from Applicant 20/12/2023